Objective To observe the effects of progressive resistance training(PRT)combined with hyperextension traction elastic pressure on pain indexes and rehabilitation outcome in patients with osteoporotic vertebral compression fracture(OVCF)after percutaneous vertebroplasty(PVP).Methods A total of 98 OVCF patients were randomly divided into observation group and control group,with 49 cases in each group.All underwent PVP following preoperative hyperextension traction elastic pressure.After operation,control group was given routine rehabilitation training,while observation group was treated with PRT in addition to routine rehabilitation training.All were intervened for 3 months.The changes of imaging indexes,lumbar pain indexes,lumbar function indexes,bone metabolism indexes and activities of daily living before,at 1 week and 3 months after operation were observed.Results Three months after operation,the anterior vertebral height was higher(P<0.05)and Cobb Angle was lower(P<0.05)in observation group than in control group.Compared with control group,observation group had lower scores on visual analog scale and Oswsetry disability index,obtained higher Japanese Orthopaedic Association score for low back pain,scored higher on activities of daily living scale,and showed lower levels of serum osteocalcin and bone specific alkaline phosphatase(all P<0.05).Conclusion Hyperextension traction elastic pressure before PVP combined with PRT after surgery can better reduce postoperative lumbar pain index,and promote bone growth,further improving lumbar function and activities of daily living in OVCF patients.

Objective:To predict the docetaxel-sensitive prostate cancer based on metabolic subtypes and biomarkers.Methods:Gene expression profiles and clinical data of prostate cancer patients were downloaded from the cancer genome atlas (TCGA) and GEO databases. Single-factor Cox regression analysis was used to screen for metabolic-related genes in prostate cancer, and a prognostic model was constructed using the glmnet package. Metabolic subtypes were classified using the ConsensusClusterPlus package. Weighted gene co-expression network was used to analyze the biomarkers of docetaxel-sensitive prostate cancer. Ribonucleotide reductase M2 ( RRM2) gene was silenced by transfection of blank vector and short hairpin RNA (shRNA) of RRM2 to inhibit its expression. The relative expression level of RRM2 protein in docetaxel-resistant PC-3-DR cells was detected by Western blotting. The effects of RRM2 on the number of colonies and the number of cells migrating to the lower chamber of PC-3-DR cells were determined by colony formation assay and cell migration assay. Results:A total of 8 genes were screened, including synaptojanin 1 ( SYNJ1), RRM2, macrophage migration inhibitory factor ( MIF), fucose-1-phosphate guanyltransferase ( FPGT), arginase 1 ( ARG1), adenosylmethionine decarboxylase 1 ( AMD1), aldo-keto reductase family 1, member B10 ( AKR1B10), and acyl-CoA synthetase short chain family member 2 ( ACSS2). A model for predicting the prognosis of prostate cancer patients was constructed, and the area under the curve for predicting 3-year disease-free survival of prostate cancer was 0.70. Three different metabolic subtypes were identified. The disease-free survival of C3 subtype was shorter ( P=0.018), and the half maximal inhibitory concentration (IC 50) of docetaxel in the C3 subtype was lower than that in the C1 and C2 subtypes (all P<0.01). The genes and biomarkers associated with docetaxel resistance were acyl-CoA oxidase 1 ( ACOX1), isocitrate dehydrogenase 1 ( IDH1), glutathione S-transferase kappa 1 ( GSTK1), sterol carrier protein 2 ( SCP2), and solute carrier family 27 member 2 ( SLC27A2). In PC-3-DR cells, the relative expression levels of RRM2 and Ki67 proteins in the transfection group (1.77±0.15, 0.52±0.08) were lower than those in the control group (3.10±0.26, 1.18±0.13), and the differences were statistically significant (all P<0.05). The number of colonies and the number of cells migrating to the lower chamber in the transfection group [(56.00±3.61, 81.67±15.82) unit] were lower than those in the control group [(151.70±7.37, 320.00±35.37) unit], and the differences were statistically significant (all P<0.05). Conclusions:The multi-gene-based prognostic model can successfully predict disease-free survival of prostate cancer patients. Advanced prostate cancer patients with C3 subtype based on metabolic genes are suitable for docetaxel-based chemotherapy.

Random systematic biopsy is the standard method for diagnosing prostate cancer. As the improvement of multi-parameter magnetic resonance imaging (mpMRI) and its corresponding scoring system, magnetic resonance imaging(MRI)-targeted target biopsy has been an effective alternative to traditional systemic puncture. Prostate imaging reporting and data system(PI-RADS) is the most commonly used MRI-scoring system. The negative rate of prostate cancer in the patient with PI-RADS scores of 1 and 2 was 90.8%(95% CI, 88.1%~93.1%), and the diagnosis rates of clinically meaningful prostate cancer in the patient with PI-RADS scores of 3, 4, and 5 was 20.9%, 58.3% and 80.7%, respectively. That means that MRI targeted prostate biopsy can more effectively detect clinically meaningful prostate cancer on the basis of reducing unnecessary punctures. There are three effective MRI guided target biopsy method for prostate biopsy, including MRI guided target biopsy(MRI-TB), MRI-TRUS fusion target biopsy(FUS-TB) and cognitive fusion target biopsy(COG-TB). Considering the false negative rate and discrepant image quality, MRI-targeted target biopsy still cannot completely replace the traditional systemic puncture. However, it can be seen that the targeted combined system puncture is the future development trend.